Joule Therapeutics develops next‑generation photosensitizers that are activated by near‑infrared light to enable deep‑tissue photodynamic therapy with selective tumor uptake and integrated imaging. Their proprietary cyanine‑salt nanomedicines aim to improve safety and efficacy for hard‑to‑treat solid tumors such as triple‑negative breast cancer and head‑and‑neck cancers, targeting oncology drug developers, research centers, and hospital oncology departments.
Funding
Funding not disclosed
Founders
Product
Problem
Current photodynamic therapy (PDT) agents have limited tumor specificity, shallow tissue penetration, and are not approved for many solid tumors such as triple‑negative breast cancer and head‑and‑neck cancers, leading to suboptimal efficacy and significant side effects.
Solution
Joule Therapeutics develops next‑generation photosensitizers based on enhanced cyanine‑salt nanomedicines that are activated by near‑infrared (NIR) light. The ion‑pairing technology yields tunable photophysical properties and selective tumor uptake, enabling deep‑tissue illumination and precise targeting of malignant cells while sparing healthy tissue. These agents also provide imaging capability for real‑time tumor visualization. The platform is being advanced for standalone and combination PDT in triple‑negative breast cancer and head‑and‑neck cancers, with preclinical data demonstrating improved safety and efficacy over existing photosensitizers.
Target Audience
Primary customers are oncology drug developers, academic cancer research centers, and hospital oncology departments seeking advanced PDT agents for hard‑to‑treat solid tumors.
Features
- Proprietary cyanine‑salt photosensitizers with NIR activation for deep tissue penetration
- Ion‑pairing nanotechnology that enhances selective tumor uptake and reduces off‑target toxicity
- Integrated imaging functionality allowing visualization of drug distribution and treatment response
- Tunable photophysical properties enabling customization for different tumor types and light delivery protocols
- Compatibility with both standalone PDT and combination regimens (e.g., with immunotherapy or radiation)